Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001

Leukemia

Volumn 16, Issue 12, 2002, Pages 2366-2378

  Mauritzson, N ^a   Albin, M ^a   Rylander, L ^a   Billstrom R ^a   Ahlgren, T ^a   Mikoczy, Z ^a   Bjork J ^a   Stromberg U ^a   Nilsson, P G ^a   Mitelman, F ^a   Hagmar, L ^a   Johansson, B ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

acute myeloid leukemia; Karyotype; Myelodysplastic syndromes; Treatment related

Indexed keywords

ACLARUBICIN; AMSACRINE; AZATHIOPRINE; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; DOXORUBICIN DERIVATIVE; ETOPOSIDE; FLUOROURACIL; HYDROXYUREA; LOMUSTINE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PIPOBROMAN; PIRARUBICIN; PROCARBAZINE; RUFOCROMOMYCIN; TENIPOSIDE; THIOTEPA; TREOSULFAN; UNINDEXED DRUG; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17; CHROMOSOME 17P; CHROMOSOME 18; CHROMOSOME 19; CHROMOSOME 20Q; CHROMOSOME 21; CHROMOSOME 3P; CHROMOSOME 5; CHROMOSOME 5Q; CHROMOSOME 7; CHROMOSOME 7Q; CHROMOSOME 8; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME INVERSION; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 3; CHROMOSOME TRANSLOCATION 8; CHROMOSOME TRANSLOCATION 9; CLINICAL FEATURE; CONTROLLED STUDY; DIPLOIDY; FEMALE; GENE FREQUENCY; GENOTOXICITY; HUMAN; KARYOTYPE; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; PLOIDY; PRIORITY JOURNAL;

EID: 0036934475     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402713     Document Type: Article

References (62)

1. Rutten FJ, Hustinx TWJ, Scheres JMJC, Wagener DJT. Trisomy-9 in the bone marrow of a patient with acute myelomonoblastic leukaemia. Br J Haematol 1974; 26: 391-394.
2. Cavallin-Ståhl E, Landberg T, Ottow Z, Mitelman F. Hodgkin's disease and acute leukaemia. A clinical and cytogenetic study. Scand J Haematol 1977; 19: 273-280.
3. Thirman MJ, Larson RA. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 1996; 10: 293-320.
4. Pedersen- Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780-2786.
5. Rowley JD, Golomb HM, Vardiman J. Nonrandom chromosomal abnormalities in acute nonlymphocytic leukemia in patients treated for Hodgkin disease and non-Hodgkin lymphomas. Blood 1977; 50: 759-770.
6. Sandberg AA, Abe S, Kowalczyk JR, Zedgenidze A, Takeuchi J, Kakati S. Chromosomes and causation of human cancer and leukemia. L. Cytogenetics of leukemias complicating other diseases. Cancer Genet Cytogenet 1982; 7: 95-136.
7. Groupe Français de Cytogénétique Hématologique. Chromosome analysis of 63 cases of secondary nonlymphoid blood disorders: a cooperative study. Cancer Genet Cytogenet 1984; 12: 95-104.
8. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986; 4: 325-345.
9. Whang-Peng J, Young RC, Lee EC, Longo DL, Schechter GP, DeVita Jr VT. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988; 71: 403-414.
10. Pedersen- Bjergaard J, Philip P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 1991; 78: 1147-1148.
11. Pui C-H, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, Mirro J Jr, Kalwinsky DK, Dahl GV, Murphy SB, Crist WM, Williams DL. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 1989; 321: 136-142.
12. Gill Super HJ, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J, Philip P, Diaz MO, Rowley JD. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 1993; 82: 3705-3711.
13. Sterkers Y, Preudhomme C, Laï J-L, Demory J-L, Caulier M-T, Wattel E, Bordessoule D, Bauters F, Fenaux P. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91: 616-622.
14. Arnold JA, Ranson SA, Abdalla SH. Azathioprine-associated acute myeloid leukaemia with trilineage dysplasia and complex karyotype: a case report and review of the literature. Clin Lab Haematol 1999; 21: 289-292.
15. Fourth International Workshop on Chromosomes in Leukemia. Secondary leukemias associated with neoplasia: treated and untreated. Cancer Genet Cytogenet 1984; 11: 319-321.
16. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992; 82: 358-367.
17. Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am 1993; 7: 81-107.
18. Ruutu T, Almqvist A, Hallman H, Honkanen T, Järvenpää E, Järventie G, Koistinen P, Koivunen F, Lahtinen R, Lehtinen M, Nousiainen T-T, Pelliniemi A, Rajamäki A, Remes K, Sarkkinen R, Sinisalo M, Timonen T, Volin L, Elonen E. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Leukemia 1994; 8: 11-15.
19. Pedersen- Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86: 3542-3552.
20. Park DJ, Koeffler HP. Therapy-related myelodysplastic syndromes. Semin Hematol 1996; 33: 256-273.
21. Cripe LD. Adult acute leukemia. Curr Probl Cancer 1997; 21: 1-64.
22. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG, Burnett AK. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML Trial (MRC AML10). Blood 1997; 89: 2311-2318.
23. Löwenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GEG, Vellenga E, Wijermans P, Berneman Z, Dekker AW, Stryckmans P, Schouten H, Jehn U, Muus P, Sonneveld P, Dardenne M, Zittoun R. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 1997; 90: 2952-2961.
24. Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. Randomized phase III study AML-9. J Clin Oncol 1998; 16: 872-881.
25. Archimbaud E, Charrin C, Magaud J-P, Campos L, Thomas X, Fière D, Rimokh R. Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint. Leukemia 1998; 12: 25-33.
26. Estey EH. Prognosis and therapy of secondary myelodysplastic syndromes. Haematologica 1998; 83: 543-549.
27. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, Balcerzak SP, Appelbaum FR. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood 1998; 91: 3607-3615.
28. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica 1999; 84: 937-945.
29. Mauritzson N, Johansson B, Albin M, Billström R, Ahlgren T, Mikoczy Z, Nilsson PG, Hagmar L, Mitelman F. A single-center population-based consecutive series of 1500 cytogenetically investigated adult hematologic malignancies: karyotypic features in relation to morphology, age and gender. Eur J Haematol 1999; 62: 95-102.
30. Mauritzson N, Johansson B, Albin M, Rylander L, Billström R, Ahlgren T, Mikoczy Z, Strömberg U, Mitelman F, Hagmar L, Nilsson PG. Survival time in a population-based consecutive series of adult acute myeloid leukemia - the prognostic impact of karyotype during the time period 1976-1993. Leukemia 2000; 14: 1039-1043.
31. Mauritzson N, Johansson B, Rylander L, Albin M, Strömberg U, Billström R, Ahlgren T, Mikoczy Z, Mitelman F, Hagmar L, Nilsson PG. The prognostic impact of karyotypic subgroups in myelodysplastic syndromes is strongly modified by sex. Br J Haematol 2001; 113: 347-356.
32. Mitelman F, Johansson B, Mertens F (eds). Mitelman Database of Chromosome Aberrations in Cancer (2001). http://cgap.nci.nih.gov/Chromosomes/Mitelman
33. Coughlin SS, Benichou J, Weed DL. Attributable risk estimation in case-control studies. Epidemiol Rev 1994; 16: 51-64.
34. Mitelman F, Manolova Y, Manolov G, Billström R, Heim S, Kristoffersson U, Mandahl N. High resolution analysis of the 5q- marker chromosome in refractory anemia. Hereditas 1986; 105: 49-54.
35. Johansson B, Mertens F, Heim S, Kristoffersson U, Mitelman F. Cytogenetics of secondary myelodysplasia (sMDS) and acute non-lymphocytic leukemia (sANLL). Eur J Haematol 1991; 47: 17-27.
36. Mertens F, Johansson B, Heim S, Kristoffersson U, Mitelman F. Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature. Leukemia 1991; 5: 214-220.
37. Billström R, Johansson H, Johansson B, Mitelman F. Immune-mediated complications in patients with myelodysplastic syndromes - clinical and cytogenetic features. Eur J Haematol 1995; 55: 42-48.
38. Höglund M, Johansson B, Pedersen-Bjergaard J, Marynen P, Mitelman F. Molecular characterization of 12p abnormalities in hematologic malignancies: deletion of KIP1, rearrangement of TEL, and amplification of CCND2. Blood 1996; 87: 324-330.
39. Johansson B, Billström R, Kristoffersson U, Åkerman M, Garwicz S, Ahlgren T, Malm C, Mitelman F. Deletion of chromosome arm 3p in hematologic malignancies. Leukemia 1997; 11: 1207-1213.
40. Andreasson P, Johansson B, Billström R, Garwicz S, Mitelman F, Höglund M. Fluorescence in situ hybridization analyses of hematologic malignancies reveal frequent cytogenetically unrecognized 12p rearrangements. Leukemia 1998; 12: 390-400.
41. Secker-Walker LM, Moorman AV, Bain BJ, Mehta AB. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. Leukemia 1998; 12: 840-844.
42. Gisselsson D, Höglund M, Mertens F, Johansson B, Dal Cin P, Van den Berghe H, Earnshaw WC, Mitelman F, Mandahl N. The structure and dynamics of ring chromosomes in human neoplastic and non-neoplastic cells. Hum Genet 1999; 104: 315-325.
43. Johansson B, Billström R, Broberg K, Fioretos T, Nilsson P-G, Ahlgren T, Malm C, Samuelsson BO, Mitelman F. Cytogenetic polyclonality in hematologic malignancies. Genes Chromosomes Cancer 1999; 24: 222-229.
44. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 1985; 65: 1364-1372.
45. Bloomfield CD. Chromosome abnormalities in secondary myelodysplastic syndromes. Scand J Haematol 1986; 36 (Suppl. 45): 82-90.
46. Pedersen- Bjergaard J, Philip P. Cytogenetic characteristics of therapy-related acute nonlymphocytic leukaemia, preleukaemia and acute myeloproliferative syndrome: correlation with clinical data for 61 consecutive cases. Br J Haematol 1987; 66: 199-207.
47. Iurlo A, Mecucci C, Van Orshoven A, Michaux JL, Boogaerts M, Noens L, Bosly A, Louwagie A, Van Den Berghe H. Cytogenetic and clinical investigations in 76 cases with therapy-related leukemia and myelodysplastic syndrome. Cancer Genet Cytogenet 1989; 43: 227-241.
48. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 1990; 76: 1083-1091.
49. Fenaux P, Laï JL, Quiquandon I, Preudhomme C, Dupriez B, Facon T, Lorthois C, Lucidarme D, Bauters F. Therapy related myelodysplastic syndrome and leukemia with no 'unfavourable' cytogenetic findings have a good response to intensive chemotherapy: a report on 15 cases. Leuk Lymphoma 1991; 5: 117-125.
50. Pedersen-Bjergaard J, Timshel S, Andersen MK, Andersen A-ST, Philip P. Cytogenetically unrelated clones in therapy-related myelodysplasia and acute myeloid leukemia: experience from the Copenhagen series updated to 180 consecutive cases. Genes Chromosomes Cancer 1998; 23: 337-349.
51. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4: 1748-1757.
52. Berger R, Flandrin G. Chromosomal abnormalities in secondary acute myeloid leukaemia and the myelodysplastic syndromes. In: Mufti GJ, Galton DAG (eds). The Myelodysplastic Syndromes. Churchill Livingstone: London, 1992, pp 129-139.
53. Boice JD Jr, Blettner M, Kleinerman RA, Stovall M, Moloney WC, Engholm G, Austin DF, Bosch A, Cookfair DL, Krementz ET, Latourette HB, Peters LJ, Schulz MD, Lundell M, Pettersson F, Storm HH, Bell CMJ, Coleman MP, Fraser P, Palmer M, Prior P, Choi NW, Hislop TG, Koch M, Robb D, Robson D, Spengler RF, von Fournier D, Frischkorn R, Lochmüller H, Pompe-Kirn V, Rimpela A, Kjørstad K, Pejovic MH, Sigurdsson K, Pisani P, Kucera H, Hutchison GB. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst 1987; 79: 1295-1311.
54. Quesnel B, Kantarjian H, Pedersen Bjergaard J, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, Bauters F, Fenaux P. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol 1993; 11: 2370-2379.
55. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Holowaty E, Karjalainen S, Langmark F, Nasca PC, Schwartz AG, Schymura MJ, Storm HH, Toogood P, Weyer P, Moloney WC. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. J Natl Cancer Inst 1994; 86: 1315-1324.
56. Andersen MK, Johansson B, Larsen SO, Pedersen-Bjergaard J. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Haematologica 1998; 83: 483-488.
57. Van Limbergen H, Poppe B, Michaux L, Herens C, Brown J, Noens L, Berneman Z, De Bock R, De Paepe A, Speleman F. Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH. Genes Chromosomes Cancer 2002; 33: 60-72.
58. Mrozek K, Heinonen K, Theil KS, Bloomfield CD. Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent over-representation of 21q, 11q, and 22q. Genes Chromosomes Cancer 2002; 34: 137-153.
59. Paulsson K, Säll T, Fioretos T, Mitelman F, Johansson B. The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. Cancer Genet Cytogenet 2001; 130: 160-165.
60. Albin M, Björk J, Welinder H, Tinnerberg H, Mauritzson N, Johansson B, Billström R, Strömberg U, Mikoczy Z, Ahlgren T, Nilsson P-G, Mitelman F, Hagmar L. Acute myeloid leukemia and clonal chromosome aberrations in relation to past exposure to organic solvents. Scand J Work Environ Health 2000; 26: 482-491.
61. Detourmignies L, Castaigne S, Stoppa AM, Harousseau JL, Sadoun A, Janvier M, Demory JL, Sanz M, Berger R, Bauters F, Chomienne C, Fenaux P. Therapy-related acute promyelocytic leukemia: a report on 16 cases. J Clin Oncol 1992; 10: 1430-1435.
62. Kudo K, Yoshida H, Kiyoi H, Numata S, Horibe K, Naoe T. Etoposide-related acute promyelocytic leukemia. Leukemia 1998; 12: 1171-1175.